Pharmacology Quiz: Vancomycin And Mrsa Coverage
20 questions · exam conditions
0:00
Vancomycin And Mrsa CoverageQuestion 1 of 20

A patient requires MRSA coverage for a confirmed bacteremia. The patient's electronic health record contains an allergy entry for vancomycin with the description: "Developed flushing and itching on my neck during the infusion 5 years ago." The patient does not recall any difficulty breathing or hives.

What is the most prudent course of action for this patient?

Avoid vancomycin and immediately start daptomycin as a safe alternative.
Perform a vancomycin skin test to rule out an IgE-mediated allergy before administration.
Prescribe linezolid, as any history of reaction to vancomycin is a contraindication to re-challenge.
Administer vancomycin with pre-medication (e.g., diphenhydramine) and a slow infusion rate of at least 2 hours.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Vancomycin And Mrsa Coverage

Practice Vancomycin And Mrsa Coverage in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Vancomycin And Mrsa Coverage, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient requires MRSA coverage for a confirmed bacteremia. The patient's electronic health record contains an allergy entry for vancomycin with the description: "Developed flushing and itching on my neck during the infusion 5 years ago." The patient does not recall any difficulty breathing or hives.

What is the most prudent course of action for this patient?

  1. Avoid vancomycin and immediately start daptomycin as a safe alternative.
  2. Perform a vancomycin skin test to rule out an IgE-mediated allergy before administration.
  3. Prescribe linezolid, as any history of reaction to vancomycin is a contraindication to re-challenge.
  4. Administer vancomycin with pre-medication (e.g., diphenhydramine) and a slow infusion rate of at least 2 hours. (correct answer)
Explanation: When evaluating drug allergies, you must distinguish between true allergic reactions and predictable side effects. This distinction determines whether a drug can be safely readministered with appropriate precautions. The patient's symptoms—flushing and itching on the neck during vancomycin infusion—are classic signs of "red man syndrome," a non-allergic, histamine-mediated reaction caused by rapid vancomycin infusion. The absence of respiratory distress, hives, or systemic symptoms makes true IgE-mediated allergy unlikely. Red man syndrome is completely preventable with slower infusion rates and antihistamine premedication. Option D is correct because it addresses red man syndrome appropriately: premedication with diphenhydramine blocks histamine release, while extending infusion time to at least 2 hours (compared to the standard 1 hour) prevents the rapid drug release that triggers this reaction. This allows safe vancomycin use, which remains first-line therapy for MRSA bacteremia. Option A is wrong because immediately avoiding vancomycin denies the patient optimal therapy based on a non-allergic reaction. Option B is incorrect because skin testing is unreliable for vancomycin and unnecessary when the reaction pattern clearly suggests red man syndrome rather than IgE-mediated allergy. Option C is wrong because it treats a manageable infusion reaction as an absolute contraindication, forcing suboptimal alternative therapy. Remember: "Red man syndrome" involves flushing and itching during vancomycin infusion without systemic allergic symptoms. It's preventable with slow infusion and premedication—don't let it prevent you from using the best antibiotic for serious MRSA infections.

Question 2

A patient with persistent MRSA bacteremia is found to have an isolate with heteroresistance to vancomycin (hVISA). The patient's vancomycin AUC/MIC ratio is optimized at 550, yet the patient remains febrile with positive follow-up blood cultures.

Which therapeutic strategy is most appropriate at this point?

  1. Increase the vancomycin dose to target an AUC/MIC ratio greater than 700.
  2. Change to a different class of anti-MRSA agent, such as daptomycin or ceftaroline. (correct answer)
  3. Add rifampin to the vancomycin regimen to penetrate a potential biofilm source.
  4. Continue current vancomycin dosing, as hVISA does not typically impact clinical outcomes.
Explanation: The correct answer is B. Heteroresistance (hVISA) is a phenomenon where a subpopulation of bacteria is less susceptible to vancomycin, which can lead to clinical failure even with optimized pharmacokinetic parameters. In cases of persistent bacteremia and documented hVISA, changing to an alternative agent with a different mechanism of action (like daptomycin or ceftaroline) is the most appropriate step. Pushing the vancomycin dose higher (Choice A) is unlikely to be effective and significantly increases the risk of toxicity. While adding rifampin (Choice C) is sometimes considered for biofilm, the primary issue here is the organism's reduced susceptibility, making a switch in the primary agent more logical. Choice D is incorrect, as hVISA is clearly associated with worse clinical outcomes.

Question 3

A patient with a moderate, non-purulent MRSA cellulitis is being considered for oral antibiotic therapy. The local MRSA isolates have a 20% rate of inducible clindamycin resistance. The patient's specific isolate has not yet undergone a D-test.

Given the local resistance patterns and lack of complete susceptibility data, which oral agent would be the most reliable empirical choice?

  1. Clindamycin
  2. Doxycycline (correct answer)
  3. Cephalexin
  4. Oral vancomycin
Explanation: The correct answer is B. Doxycycline is a reliable option for many community-acquired MRSA skin infections and its efficacy is not affected by the mechanism of inducible clindamycin resistance. Choice A, clindamycin, is a poor choice without a negative D-test, as there is a significant risk of clinical failure if inducible resistance is present. Choice C, cephalexin, is a first-generation cephalosporin and lacks activity against MRSA. Choice D, oral vancomycin, is not systemically absorbed and is only used for the treatment of Clostridioides difficile colitis.

Question 4

A 75-kg patient with MRSA pneumonia receives vancomycin 1250 mg IV every 12 hours. A pharmacokinetic analysis based on two serum levels estimates the 24-hour Area Under the Curve (AUC24) to be 500 mg*h/L. The MRSA isolate has an MIC of 1 mcg/mL.

How should the clinician interpret these results and manage the patient's therapy?

  1. The AUC/MIC ratio is sub-therapeutic (<400); therefore, the vancomycin dose should be increased.
  2. The AUC/MIC ratio is within the therapeutic goal (400-600); the current regimen should be continued. (correct answer)
  3. The AUC/MIC ratio is potentially toxic (>600); therefore, the vancomycin dose should be decreased.
  4. The trough level must be measured, as it is a more reliable target for efficacy than the AUC/MIC ratio.
Explanation: The correct answer is B. The first step is to calculate the AUC/MIC ratio: AUC (500) / MIC (1) = 500. The second step is to compare this to the therapeutic goal for serious MRSA infections, which is an AUC/MIC ratio of 400-600. Since 500 falls within this range, the current dose is appropriate and should be continued with routine safety and efficacy monitoring. Choices A and C are incorrect because their interpretation of the calculated AUC/MIC ratio is wrong. Choice D is incorrect as current guidelines endorse the AUC/MIC ratio as the most accurate predictor of both efficacy and nephrotoxicity, making it superior to trough-only monitoring.

Question 5

A culture from a chronic diabetic foot ulcer grows Staphylococcus aureus. The susceptibility report shows a vancomycin MIC of 32 mcg/mL and the presence of the mecA gene.

Based on this resistance profile, which of the following agents represents a viable treatment option?

  1. Nafcillin
  2. Vancomycin, administered via continuous infusion.
  3. Ceftriaxone
  4. Linezolid (correct answer)
Explanation: The correct answer is D. This organism is both methicillin-resistant (mecA positive) and vancomycin-resistant (VRSA, with an MIC > 16 mcg/mL). Therefore, both beta-lactams like nafcillin (Choice A) and vancomycin (Choice B) would be ineffective. Ceftriaxone (Choice C) does not have activity against MRSA. Agents with activity against VRSA, such as linezolid or daptomycin, are required for treatment.

Question 6

A 68-year-old male is being treated for MRSA bacteremia with intravenous vancomycin. The institutional goal is to achieve an AUC/MIC ratio between 400 and 600. The patient's most recent vancomycin trough level is 18 mg/L. A pharmacist calculates the 24-hour AUC to be 385 mg*h/L based on a two-level pharmacokinetic assessment. The MRSA isolate has a reported MIC of 1 mcg/mL.

Based on these findings, what is the most appropriate action regarding the patient's vancomycin therapy?

  1. Continue the current dose, as the trough level of 18 mg/L is within the traditional therapeutic range of 15-20 mg/L.
  2. Increase the vancomycin dose or frequency, as the AUC/MIC ratio is sub-therapeutic. (correct answer)
  3. Decrease the vancomycin dose, as the trough level of 18 mg/L is associated with an increased risk of nephrotoxicity.
  4. Switch therapy to daptomycin, as the current regimen is likely to fail due to pharmacokinetic limitations.
Explanation: The correct answer is B. The primary pharmacodynamic target for vancomycin efficacy is an AUC/MIC ratio of 400-600. In this case, the calculated AUC/MIC is 385/1 = 385, which is below the therapeutic target. Therefore, the dose or frequency should be increased. Choice A is incorrect because while the trough is within the traditional range, it is being used as a surrogate for the more accurate AUC/MIC target, which is not being met. Choice C is incorrect because the current regimen is sub-therapeutic, and decreasing the dose would worsen this. Choice D is premature; the current regimen should be optimized before switching to an alternative agent.

Question 7

A microbiology report for an MRSA isolate from a wound culture shows the following preliminary results: Erythromycin - Resistant; Clindamycin - Susceptible.

Before finalizing a decision to treat the patient with oral clindamycin, what additional laboratory test is essential?

  1. A test for vancomycin susceptibility (MIC).
  2. A beta-lactamase production test.
  3. A minimum bactericidal concentration (MBC) test.
  4. A disk diffusion test for inducible resistance (D-test). (correct answer)
Explanation: When you encounter an MRSA isolate that's erythromycin-resistant but clindamycin-susceptible, you need to consider the mechanism of macrolide-lincosamide resistance. These antibiotics share similar binding sites on the bacterial ribosome, and resistance can be constitutive (always present) or inducible (triggered by exposure to certain antibiotics like erythromycin). The D-test (double-disk diffusion test) is essential here because it detects inducible clindamycin resistance. In this test, erythromycin and clindamycin disks are placed near each other on the culture plate. If the bacteria have inducible resistance genes (like erm genes), erythromycin will induce resistance to clindamycin, creating a characteristic "D-shaped" zone of inhibition around the clindamycin disk. Without this test, you might miss resistance that could develop during clindamycin therapy, leading to treatment failure. Option A (vancomycin MIC) is important for MRSA generally but doesn't address the specific clindamycin resistance concern here. Option B (beta-lactamase test) is irrelevant since MRSA resistance involves altered penicillin-binding proteins, not beta-lactamases, and we're not using beta-lactams anyway. Option C (MBC test) determines bactericidal concentrations but won't reveal inducible resistance mechanisms. Remember this pattern: whenever you see erythromycin resistance with clindamycin susceptibility in gram-positive cocci, always think "D-test" before using clindamycin. This is a classic microbiology board question that tests your understanding of inducible resistance mechanisms.

Question 8

A patient with end-stage renal disease on hemodialysis develops MRSA bacteremia that persists despite appropriately dosed vancomycin. Molecular analysis of the bacterial isolate reveals the presence of the vanA gene.

The presence of this gene confers vancomycin resistance by modifying which bacterial structure?

  1. Penicillin-binding protein (PBP), leading to reduced beta-lactam affinity.
  2. The 30S ribosomal subunit, preventing protein synthesis.
  3. The D-alanyl-D-alanine terminus of peptidoglycan precursors. (correct answer)
  4. The bacterial cell membrane, causing rapid depolarization.
Explanation: The correct answer is C. The vanA gene cluster encodes enzymes that alter the terminus of the peptidoglycan precursor from D-alanyl-D-alanine to D-alanyl-D-lactate. Vancomycin cannot effectively bind to this altered structure, leading to high-level resistance (VRSA). Choice A describes the mechanism of methicillin resistance (mecA gene encoding PBP2a). Choice B is the target of aminoglycosides and tetracyclines. Choice D describes the mechanism of action of daptomycin.

Question 9

A patient with MRSA endocarditis has an isolate with a vancomycin MIC of 1.5 mcg/mL and a fluctuating creatinine clearance of 30-40 mL/min. The clinical team is finding it difficult to achieve a target AUC/MIC of 400-600 with intermittent dosing without causing troughs to exceed 20 mg/L.

Which dosing strategy offers a pharmacokinetic advantage for achieving the therapeutic goal while potentially minimizing toxicity risk in this patient?

  1. Administering vancomycin as a continuous intravenous infusion. (correct answer)
  2. Increasing the intermittent dose and extending the interval to every 48 hours.
  3. Switching to linezolid to avoid the complexities of vancomycin dosing.
  4. Maintaining the current dose but adding rifampin for its synergistic effect.
Explanation: The correct answer is A. A continuous infusion of vancomycin maintains a steady serum concentration, which makes it easier to achieve the target AUC without the high peaks (Cmax) and troughs seen with intermittent dosing. This can be particularly useful in patients with fluctuating renal function or when targeting higher AUCs for isolates with elevated MICs, as it may reduce the risk of nephrotoxicity associated with high peak concentrations. Switching agents (Choice C) is an option, but the question asks for the best dosing strategy for vancomycin. Adding rifampin (Choice D) addresses synergy, not the primary pharmacokinetic challenge. Extending the interval (Choice B) can make it even harder to consistently achieve the AUC target.

Question 10

A patient with end-stage renal disease on hemodialysis develops MRSA bacteremia that persists despite appropriately dosed vancomycin. Molecular analysis of the bacterial isolate reveals the presence of the vanA gene.

The presence of this gene confers vancomycin resistance by modifying which bacterial structure?

  1. Penicillin-binding protein (PBP), leading to reduced beta-lactam affinity.
  2. The 30S ribosomal subunit, preventing protein synthesis.
  3. The D-alanyl-D-alanine terminus of peptidoglycan precursors. (correct answer)
  4. The bacterial cell membrane, causing rapid depolarization.
Explanation: The correct answer is C. The vanA gene cluster encodes enzymes that alter the terminus of the peptidoglycan precursor from D-alanyl-D-alanine to D-alanyl-D-lactate. Vancomycin cannot effectively bind to this altered structure, leading to high-level resistance (VRSA). Choice A describes the mechanism of methicillin resistance (mecA gene encoding PBP2a). Choice B is the target of aminoglycosides and tetracyclines. Choice D describes the mechanism of action of daptomycin.

Question 11

A 68-year-old male is being treated for MRSA bacteremia with intravenous vancomycin. The institutional goal is to achieve an AUC/MIC ratio between 400 and 600. The patient's most recent vancomycin trough level is 18 mg/L. A pharmacist calculates the 24-hour AUC to be 385 mg*h/L based on a two-level pharmacokinetic assessment. The MRSA isolate has a reported MIC of 1 mcg/mL.

Based on these findings, what is the most appropriate action regarding the patient's vancomycin therapy?

  1. Continue the current dose, as the trough level of 18 mg/L is within the traditional therapeutic range of 15-20 mg/L.
  2. Increase the vancomycin dose or frequency, as the AUC/MIC ratio is sub-therapeutic. (correct answer)
  3. Decrease the vancomycin dose, as the trough level of 18 mg/L is associated with an increased risk of nephrotoxicity.
  4. Switch therapy to daptomycin, as the current regimen is likely to fail due to pharmacokinetic limitations.
Explanation: The correct answer is B. The primary pharmacodynamic target for vancomycin efficacy is an AUC/MIC ratio of 400-600. In this case, the calculated AUC/MIC is 385/1 = 385, which is below the therapeutic target. Therefore, the dose or frequency should be increased. Choice A is incorrect because while the trough is within the traditional range, it is being used as a surrogate for the more accurate AUC/MIC target, which is not being met. Choice C is incorrect because the current regimen is sub-therapeutic, and decreasing the dose would worsen this. Choice D is premature; the current regimen should be optimized before switching to an alternative agent.

Question 12

A patient with an MRSA prosthetic knee infection has been receiving IV vancomycin for four weeks with therapeutic trough concentrations. Despite this, the patient shows minimal clinical improvement, with persistent joint effusion and elevated inflammatory markers. A repeat aspirate culture grows MRSA with a vancomycin MIC of 2 mcg/mL, reported as 'Susceptible' by the lab.

Which of the following best explains the likely reason for treatment failure in this patient?

  1. The development of true vancomycin resistance mediated by the vanA gene cluster.
  2. Poor penetration of vancomycin into the infected prosthetic joint and surrounding biofilm.
  3. Reduced clinical efficacy of vancomycin against isolates with MIC values at the higher end of the susceptible range. (correct answer)
  4. An antagonistic interaction between vancomycin and anti-inflammatory medications used for pain control.
Explanation: The correct answer is C. Clinical data has consistently shown higher rates of treatment failure for serious MRSA infections, such as bacteremia and endocarditis, when the vancomycin MIC is ≥1.5 mcg/mL, even though the breakpoint for susceptibility is ≤2 mcg/mL. This phenomenon is often referred to as 'MIC creep'. Choice A is incorrect; vanA-mediated resistance would result in a very high MIC (>16 mcg/mL), characteristic of VRSA, not an MIC of 2 mcg/mL. Choice B is a contributing factor in any prosthetic infection, but the key piece of new information is the elevated MIC, which directly impacts pharmacodynamic efficacy. Choice D is not a recognized or common interaction.

Question 13

A patient with a moderate, non-purulent MRSA cellulitis is being considered for oral antibiotic therapy. The local MRSA isolates have a 20% rate of inducible clindamycin resistance. The patient's specific isolate has not yet undergone a D-test.

Given the local resistance patterns and lack of complete susceptibility data, which oral agent would be the most reliable empirical choice?

  1. Clindamycin
  2. Doxycycline (correct answer)
  3. Cephalexin
  4. Oral vancomycin
Explanation: The correct answer is B. Doxycycline is a reliable option for many community-acquired MRSA skin infections and its efficacy is not affected by the mechanism of inducible clindamycin resistance. Choice A, clindamycin, is a poor choice without a negative D-test, as there is a significant risk of clinical failure if inducible resistance is present. Choice C, cephalexin, is a first-generation cephalosporin and lacks activity against MRSA. Choice D, oral vancomycin, is not systemically absorbed and is only used for the treatment of Clostridioides difficile colitis.

Question 14

A patient with MRSA meningitis secondary to a neurosurgical procedure is being treated with intravenous vancomycin. The patient's meninges are known to be inflamed.

Which statement accurately describes a critical pharmacokinetic consideration for vancomycin in this clinical setting?

  1. Vancomycin has excellent baseline penetration into the central nervous system, ensuring therapeutic concentrations.
  2. Penetration of vancomycin into the cerebrospinal fluid (CSF) is poor but is significantly enhanced by meningeal inflammation. (correct answer)
  3. Intrathecal administration is always required as a first-line approach for MRSA meningitis.
  4. Vancomycin is actively transported out of the CSF, a process that is inhibited by probenecid co-administration.
Explanation: The correct answer is B. Vancomycin is a large, hydrophilic molecule that normally has very poor penetration across the blood-brain barrier. However, during meningitis, inflammation disrupts the barrier, allowing for increased, albeit variable, penetration of vancomycin into the CSF, often reaching therapeutic levels. Choice A is incorrect; baseline penetration is poor. Choice C is incorrect; high-dose IV vancomycin is the standard initial approach, with intrathecal therapy reserved for refractory cases. Choice D describes an efflux pump mechanism relevant to some beta-lactams but not primarily to vancomycin.

Question 15

A patient is being discharged with a prescription for an oral antibiotic to treat a well-demarcated MRSA skin infection. The isolate is susceptible to linezolid, doxycycline, and trimethoprim-sulfamethoxazole. The patient's medication list includes sertraline, an SSRI, for depression.

Which oral MRSA agent requires careful monitoring and patient education due to a potential for a serious drug interaction with sertraline?

  1. Linezolid (correct answer)
  2. Trimethoprim-sulfamethoxazole
  3. Doxycycline
  4. Minocycline
Explanation: When you encounter questions about drug interactions, always consider the mechanisms by which medications affect neurotransmitter systems, especially serotonin. This question tests your knowledge of a potentially life-threatening interaction between certain antibiotics and antidepressants. Linezolid (A) is the correct answer because it has weak monoamine oxidase inhibitor (MAOI) activity. When combined with sertraline, an SSRI that increases serotonin levels, this can lead to serotonin syndrome - a dangerous condition characterized by altered mental status, hyperthermia, muscle rigidity, and autonomic instability. The combination of increased serotonin from the SSRI and decreased serotonin breakdown from linezolid's MAOI effect creates this risk. Trimethoprim-sulfamethoxazole (B) doesn't have significant interactions with SSRIs through serotonin pathways. While it can interact with other medications like warfarin, it doesn't pose the serotonin syndrome risk that makes linezolid dangerous with sertraline. Doxycycline (C) has minimal drug interactions with SSRIs. Its primary interactions involve absorption issues with minerals and some hepatic enzyme effects, but not serotonin-related mechanisms. Minocycline (D) is similar to doxycycline and doesn't have clinically significant interactions with SSRIs that would require special monitoring for serotonin syndrome. Remember this key pattern: linezolid + any serotonergic medication (SSRIs, SNRIs, tricyclics, MAOIs) = potential serotonin syndrome. Always check for psychiatric medications when considering linezolid therapy, and know that this interaction may require choosing an alternative antibiotic or psychiatric medication.

Question 16

A 42-year-old female patient with a body mass index (BMI) of 45 kg/m² requires vancomycin for a deep-seated MRSA abscess. Her renal function is normal, with an estimated creatinine clearance of 135 mL/min.

Which pharmacokinetic principle is most critical to apply when designing a maintenance dosing regimen for this patient?

  1. Vancomycin clearance is significantly reduced in obese patients, requiring lower maintenance doses.
  2. The volume of distribution for vancomycin is best estimated using ideal body weight in obese patients.
  3. Vancomycin half-life is unpredictable in obesity, so trough-only monitoring is the most reliable strategy.
  4. Obese patients with normal serum creatinine often exhibit augmented renal clearance, necessitating higher or more frequent doses. (correct answer)
Explanation: When you encounter vancomycin dosing questions involving obese patients, focus on how obesity affects both renal function and drug clearance, even when standard kidney markers appear normal. The key insight here is recognizing augmented renal clearance (ARC) in obesity. Despite this patient's normal serum creatinine, her elevated creatinine clearance of 135 mL/min (normal is ~120 mL/min) indicates enhanced kidney function. Obese patients often exhibit ARC due to increased cardiac output, renal blood flow, and glomerular hyperfiltration. Since vancomycin is primarily eliminated renally, this enhanced clearance means the drug will be removed from the body faster than expected, requiring higher or more frequent maintenance doses to achieve therapeutic levels. This makes option D correct. Option A is wrong because vancomycin clearance is actually increased, not reduced, in obese patients with normal kidney function. Option B incorrectly suggests using ideal body weight for volume of distribution calculations—while ideal body weight is used for clearance estimates, vancomycin's volume of distribution correlates better with actual body weight since it distributes into extracellular fluid, which increases with body mass. Option C mischaracterizes the monitoring approach; while vancomycin half-life can vary in obesity, this doesn't make trough-only monitoring the "most reliable" strategy—comprehensive monitoring considering both pharmacokinetics and patient factors is preferred. Remember: in obese patients with normal creatinine, always consider augmented renal clearance. Don't assume "normal" lab values mean standard dosing will work—obesity significantly alters drug pharmacokinetics beyond what routine labs reveal.

Question 17

A patient requires MRSA coverage for a confirmed bacteremia. The patient's electronic health record contains an allergy entry for vancomycin with the description: "Developed flushing and itching on my neck during the infusion 5 years ago." The patient does not recall any difficulty breathing or hives.

What is the most prudent course of action for this patient?

  1. Avoid vancomycin and immediately start daptomycin as a safe alternative.
  2. Perform a vancomycin skin test to rule out an IgE-mediated allergy before administration.
  3. Prescribe linezolid, as any history of reaction to vancomycin is a contraindication to re-challenge.
  4. Administer vancomycin with pre-medication (e.g., diphenhydramine) and a slow infusion rate of at least 2 hours. (correct answer)
Explanation: When evaluating drug allergies, you must distinguish between true allergic reactions and predictable side effects. This distinction determines whether a drug can be safely readministered with appropriate precautions. The patient's symptoms—flushing and itching on the neck during vancomycin infusion—are classic signs of "red man syndrome," a non-allergic, histamine-mediated reaction caused by rapid vancomycin infusion. The absence of respiratory distress, hives, or systemic symptoms makes true IgE-mediated allergy unlikely. Red man syndrome is completely preventable with slower infusion rates and antihistamine premedication. Option D is correct because it addresses red man syndrome appropriately: premedication with diphenhydramine blocks histamine release, while extending infusion time to at least 2 hours (compared to the standard 1 hour) prevents the rapid drug release that triggers this reaction. This allows safe vancomycin use, which remains first-line therapy for MRSA bacteremia. Option A is wrong because immediately avoiding vancomycin denies the patient optimal therapy based on a non-allergic reaction. Option B is incorrect because skin testing is unreliable for vancomycin and unnecessary when the reaction pattern clearly suggests red man syndrome rather than IgE-mediated allergy. Option C is wrong because it treats a manageable infusion reaction as an absolute contraindication, forcing suboptimal alternative therapy. Remember: "Red man syndrome" involves flushing and itching during vancomycin infusion without systemic allergic symptoms. It's preventable with slow infusion and premedication—don't let it prevent you from using the best antibiotic for serious MRSA infections.

Question 18

A culture from a chronic diabetic foot ulcer grows Staphylococcus aureus. The susceptibility report shows a vancomycin MIC of 32 mcg/mL and the presence of the mecA gene.

Based on this resistance profile, which of the following agents represents a viable treatment option?

  1. Nafcillin
  2. Vancomycin, administered via continuous infusion.
  3. Ceftriaxone
  4. Linezolid (correct answer)
Explanation: The correct answer is D. This organism is both methicillin-resistant (mecA positive) and vancomycin-resistant (VRSA, with an MIC > 16 mcg/mL). Therefore, both beta-lactams like nafcillin (Choice A) and vancomycin (Choice B) would be ineffective. Ceftriaxone (Choice C) does not have activity against MRSA. Agents with activity against VRSA, such as linezolid or daptomycin, are required for treatment.

Question 19

A 75-kg patient with MRSA pneumonia receives vancomycin 1250 mg IV every 12 hours. A pharmacokinetic analysis based on two serum levels estimates the 24-hour Area Under the Curve (AUC24) to be 500 mg*h/L. The MRSA isolate has an MIC of 1 mcg/mL.

How should the clinician interpret these results and manage the patient's therapy?

  1. The AUC/MIC ratio is sub-therapeutic (<400); therefore, the vancomycin dose should be increased.
  2. The AUC/MIC ratio is within the therapeutic goal (400-600); the current regimen should be continued. (correct answer)
  3. The AUC/MIC ratio is potentially toxic (>600); therefore, the vancomycin dose should be decreased.
  4. The trough level must be measured, as it is a more reliable target for efficacy than the AUC/MIC ratio.
Explanation: The correct answer is B. The first step is to calculate the AUC/MIC ratio: AUC (500) / MIC (1) = 500. The second step is to compare this to the therapeutic goal for serious MRSA infections, which is an AUC/MIC ratio of 400-600. Since 500 falls within this range, the current dose is appropriate and should be continued with routine safety and efficacy monitoring. Choices A and C are incorrect because their interpretation of the calculated AUC/MIC ratio is wrong. Choice D is incorrect as current guidelines endorse the AUC/MIC ratio as the most accurate predictor of both efficacy and nephrotoxicity, making it superior to trough-only monitoring.

Question 20

A patient with MRSA endocarditis has an isolate with a vancomycin MIC of 1.5 mcg/mL and a fluctuating creatinine clearance of 30-40 mL/min. The clinical team is finding it difficult to achieve a target AUC/MIC of 400-600 with intermittent dosing without causing troughs to exceed 20 mg/L.

Which dosing strategy offers a pharmacokinetic advantage for achieving the therapeutic goal while potentially minimizing toxicity risk in this patient?

  1. Administering vancomycin as a continuous intravenous infusion. (correct answer)
  2. Increasing the intermittent dose and extending the interval to every 48 hours.
  3. Switching to linezolid to avoid the complexities of vancomycin dosing.
  4. Maintaining the current dose but adding rifampin for its synergistic effect.
Explanation: The correct answer is A. A continuous infusion of vancomycin maintains a steady serum concentration, which makes it easier to achieve the target AUC without the high peaks (Cmax) and troughs seen with intermittent dosing. This can be particularly useful in patients with fluctuating renal function or when targeting higher AUCs for isolates with elevated MICs, as it may reduce the risk of nephrotoxicity associated with high peak concentrations. Switching agents (Choice C) is an option, but the question asks for the best dosing strategy for vancomycin. Adding rifampin (Choice D) addresses synergy, not the primary pharmacokinetic challenge. Extending the interval (Choice B) can make it even harder to consistently achieve the AUC target.